BTIG Research Reaffirms “Buy” Rating for Billiontoone (NASDAQ:BLLN)

Billiontoone (NASDAQ:BLLN)‘s stock had its “buy” rating reaffirmed by research analysts at BTIG Research in a report released on Thursday, MarketBeat.com reports. They currently have a $130.00 price objective on the stock. BTIG Research‘s price target suggests a potential upside of 14.15% from the stock’s current price.

A number of other research analysts have also issued reports on BLLN. Guggenheim boosted their price target on shares of Billiontoone from $125.00 to $128.00 and gave the stock a “buy” rating in a research note on Thursday, October 1st. Zacks Research raised Billiontoone from a “strong sell” rating to a “hold” rating in a report on Friday, October 2nd. JPMorgan Chase & Co. decreased their price target on Billiontoone from $145.00 to $130.00 and set an “overweight” rating on the stock in a research note on Thursday, August 6th. Canaccord Genuity Group began coverage on Billiontoone in a research report on Wednesday, September 2nd. They issued a “buy” rating and a $120.00 price objective for the company. Finally, Wall Street Zen downgraded Billiontoone from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Seven research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Billiontoone currently has an average rating of “Moderate Buy” and an average price target of $126.25.

Billiontoone Trading Up 3.1%

BLLN opened at $113.89 on Thursday. Billiontoone has a 52 week low of $61.96 and a 52 week high of $150.44. The firm has a market cap of $5.37 billion and a price-to-earnings ratio of 162.70. The business’s 50 day moving average is $104.67 and its two-hundred day moving average is $96.89. The company has a quick ratio of 11.31, a current ratio of 11.69 and a debt-to-equity ratio of 0.17.

Billiontoone (NASDAQ:BLLN) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.15 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.15. Billiontoone had a return on equity of 9.96% and a net margin of 8.04%. The company had revenue of $109.45 million during the quarter. On average, research analysts predict that Billiontoone will post 0.80 EPS for the current year.

Insider Transactions at Billiontoone

In related news, SVP Bosch John Roderick Ten sold 2,834 shares of the company’s stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $113.17, for a total transaction of $320,723.78. Following the transaction, the senior vice president owned 16,551 shares of the company’s stock, valued at approximately $1,873,076.67. This represents a 14.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Oguzhan Atay sold 25,001 shares of the firm’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $109.24, for a total transaction of $2,731,109.24. Following the sale, the chief executive officer owned 16,667 shares in the company, valued at approximately $1,820,703.08. This trade represents a 60.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 264,194 shares of company stock worth $27,797,333 over the last ninety days. 50.22% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Penn Capital Management Company LLC grew its holdings in Billiontoone by 2.3% in the third quarter. Penn Capital Management Company LLC now owns 132,636 shares of the company’s stock valued at $14,143,000 after purchasing an additional 3,034 shares during the period. Parallel Advisors LLC raised its stake in Billiontoone by 86.7% during the third quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock worth $30,000 after purchasing an additional 130 shares during the period. Provenance Wealth Advisors LLC acquired a new position in shares of Billiontoone in the 3rd quarter valued at $56,000. D.A. Davidson & CO. acquired a new position in shares of Billiontoone in the 3rd quarter valued at $773,000. Finally, Forum Financial Management LP purchased a new stake in shares of Billiontoone during the 3rd quarter valued at $274,000.

More Billiontoone News

Here are the key news stories impacting Billiontoone this week:

• Positive Sentiment: Q3 results beat estimates: Revenue was approximately $123 million, above the $115.8 million FactSet estimate. Reports put quarterly EPS at either $0.32 or $0.48, both above the $0.16 consensus; the reports differ on the EPS figure. Q3 earnings report
• Positive Sentiment: Raised outlook and upcoming launch: BillionToOne lifted its 2026 revenue guidance to $460 million–$470 million and said it plans to launch Northstar Clear on December 15. Higher guidance and a new product launch may support expectations for growth. Guidance and Northstar Clear announcement
• Negative Sentiment: Executives reported stock sales: CEO Oguzhan Atay, CTO David Tsao and SVP Bosch John Roderick Ten sold shares on November 2. The sales were conducted under pre-arranged Rule 10b5-1 plans, which may reduce—but do not eliminate—the concern investors could attach to insider selling. Insider transaction report

Billiontoone Company Profile

BillionToOne, Inc is a molecular diagnostics company that develops tests designed to provide more sensitive and quantitative genetic information from blood samples. The company’s technology is based on its proprietary Quantitative Counting Template (QCT) platform, which is designed to measure DNA molecules with high sensitivity and support the detection of clinically meaningful genetic signals.

The company’s products include prenatal diagnostic and screening solutions marketed under the UNITY brand.